Thoratec scored the FDA's blessing to market a next-generation controller for the HeartMate II implant, giving the company a user-friendly face for its market-leading left ventricular assist device.
Thanks to a 15.5% leap in sales for its signature devices, Thoratec posted a 17% revenue jump in the fourth quarter, and the devicemaker expects to keep cashing in through 2013.
Thoratec's push to keep sales surging for its HeartMate II pump will move to Japan, now that regulators have signed off on the device. Plans call for a commercial launch to begin at the end of the 2013 first quarter.
Despite a jump in device sales, Thoratec's second-quarter profits declined 2.8%, spurred by a 20% increase in operating expenses.
Despite ceding the reins to Omar Ishrak in June 2011, former Medtronic CEO William Hawkins made just over $8 million in 2012.
Thoratec ($THOR) credited a U.S. and global sales surge of its HeartMate II pump in large part with boosting 2012 first-quarter revenue 27% compared with a year earlier.
The FDA slapped Thoratec ($THOR) with a Class 1 recall status --the most serious--for the company's HeartMate II pump, after the company issued new instructions to clinicians in order to prevent them from improperly implanting the device.
The board of Thoratec ( $THOR ) is being urged by shareholder Oracle Investment Management to find a suitable buyer because the implantable heart pump maker has proven "unable to maximize shareholder
It's earnings time again, and analysts are making their predictions about the fates of companies. In his latest investor note, Canaccord Genuity analyst Jason Mills names 5 medtech companies that he